Publications of Faculty of Medicine:Prognostic Significance of 07, MIB-1 and CD44 in Cancer Prostate: Abstract

Prognostic Significance of 07, MIB-1 and CD44 in Cancer Prostate
Full paper Not Available

The quest for prognostic molecular markers in prostatic carcinoma is still in progress. Many proteins have already been screened by immunohistochemistry aiming to find the most reliable indicator of progressive disease. We substantiate the prognostic value of 3 tissue markers, the cell cycle proteins p27 (kip I) and MIS-1 and the cell adhesion protein CD44s. Materials and Methods: We studied selected 100 patients with prostatic carcinoma in the period from 1999 to 2004 who did not receive radiation, hormonal therapy, or chemotherapy before surgery. Representative tumor sections were immunohistochemically stained with antibodies against p27 (kipl), MIB-1 (Ki-67) and CD44s and assessed in a semiquantitative manner. Gleason score and pathological tumor stage were recorded. We have evaluated the relationship between expression of these proteins and clinicopathological parameters such as tumor nuclear grade, pathological stage. Gleason score and lymph node invasion. All variables were correlated with clinical progression and disease specific survival on univariate and multivariate analyses. The present study was undertaken to investigate the degree of expression of CD44. P27 and Ki-67 (MIS-1) by immunohistochemistry us a predictor of the clinical behavior in prostatic carcinoma. Results: Statistically highly significant inverse relationship (p<0.01) was seen between reduced CD44 expression and tumor stage. Gleason sum score and lymph node invasion. statistically significant direct relationship (p<0.05) was seen between MIS- I and p27 expression in one side and tumor grade, stage and Gleason sum score on the other side. Conclusions: This study highlighted the role of CD44, MIS-1 and p27 immunoreactivity in prostate cancer progression, they could be used as valuable prognostic parameters in prostate cancer and their associated expression may provide additional prognostic advantage for undetermined cases of aggressive potentiality. Reduced p27 (kip I) and increased MIS- I expression are independent predictors of poor outcome in prostate cancer. Decreased expression of CD44s yields additional information in predicting poor clinical outcome. These tissue markers may identify patients clinical outcome that may benefit from adjuvant therapy